We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Spruce Biosciences Inc (SPRB) USD0.0001

Sell:$4.48 Buy:$4.55 Change: $0.25 (5.29%)
Market closed |  Prices as at close on 15 October 2021 | Switch to live prices |
Sell:$4.48
Buy:$4.55
Change: $0.25 (5.29%)
Market closed |  Prices as at close on 15 October 2021 | Switch to live prices |
Sell:$4.48
Buy:$4.55
Change: $0.25 (5.29%)
Market closed |  Prices as at close on 15 October 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for rare endocrine disorders. The Company's development product candidate, tildacerfont, is a non-steroidal therapy that offers disease control for patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is a potent and selective, non-steroidal, oral, small-molecule antagonist of the corticotropin-releasing hormone receptor 1 (CRF1) receptor, which is a regulator of the production of adrenocorticotropic hormone (ACTH). Its CAHmelia-203, is a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with CAH with poor disease control. Its CAHmelia-204, is a second Phase IIb clinical trial in adult patients with CAH with good disease control focused on glucocorticoid reduction. It has also conducted two Phase IIa clinical trials of tildacerfont in adult patients with CAH on stable glucocorticoid therapy.

Contact details

Address:
2001 Junipero Serra Blvd., Suite 640
DALY CITY
94104-5401
United States
Telephone:
+1 (302) 6365400
Website:
www.sprucebiosciences.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SPRB
ISIN:
US85209E1091
Market cap:
$114.55 million
Shares in issue:
23.38 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Michael Grey
    Executive Chairman of the Board
  • Richard King
    Chief Executive Officer, Director
  • Samir Gharib
    Chief Financial Officer
  • Rosh Dias
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.